Jonathan McNeill - 10 Dec 2021 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Reporting relationship: Senior Vice President of Business Development
Issuer ticker: DYN
Reported as of: 10 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Dec 2021, 15:22:18 UTC
Prior SEC filing: 22 Sep 2021
Next SEC filing: 14 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Richard Scalzo, Attorney-in-Fact

Key filing fact

Jonathan McNeill filed Form 4 for Dyne Therapeutics, Inc. (DYN) on 14 Dec 2021.

Key facts

This page summarizes Jonathan McNeill's Form 4 filing for Dyne Therapeutics, Inc. (DYN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Dec 2021, 15:22.

Change

Previous filing in this sequence was filed on 22 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DYN transaction

Common Stock

Award

Transaction value: $0
Shares: +25,311
Change %: +71%
Price: $0.000000
Shares after: 60,947
Date: 10 Dec 2021
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DYN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +37,967
Change %
Price: $0.000000
Shares after: 37,967
Date: 10 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,967
Exercise price: $13.12
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Consists of shares of Common Stock issuable under 25,311 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022.

Footnote F2

Includes 38,070 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting.

Footnote F3

This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025.

SEC remarks

Senior Vice President of Business Development